Background and Objectives Refrigeration (cold-storage) of pathogen inactivated (PI) platelet components may increase the shelf-life and safety profile of platelet components, compared to conventional room-temperature (RT) storage. Whilst there is substantial knowledge regarding the impact of these individual treatments on platelets, the combined effect has not been assessed.
Introduction
Platelets are currently stored at 22-24°C with constant agitation. This method of storage is associated with an increased risk of bacterial proliferation as well as a decrease in platelet quality over storage due to continued metabolic activity, referred to as the platelet storage lesion [1] . These detrimental aspects of room temperature (RT) storage limit the platelet shelf-life to between five and seven days, depending on the country, leading to logistic issues in maintaining sufficient inventory.
Cold-storage or refrigeration of platelets at 2-6°C is (re)emerging as an attractive method of storing platelets. Platelets are not routinely stored at refrigerated temperatures due to them being rapidly cleared from the circulation upon transfusion [2, 3] . However, there is growing global interest in cold-storing platelets because of the potential for a longer shelf-life and improved haemostatic function [4, 5] . In vitro data demonstrate cold-stored platelets have reduced glycolytic metabolism, reduced granule release, increased phosphatidylserine and P-selectin exposure, activation of the GPIIb/IIIa receptor, and improved haemostatic parameters [6] [7] [8] [9] [10] . While it has been shown that platelet refrigeration reduces bacterial proliferation [11] , it does not eliminate the risk of all transfusion transmitted infections.
Pathogen inactivation (PI) systems are able to inactivate a broad range of pathogens, including bacteria, viruses and parasites. PI of platelet products using the INTERCEPT (Cerus Corporation; Concord, CA, USA) and Mirasol systems (TerumoBCT, Lakewood, CO, USA) has become routine in many blood centres throughout Europe and the INTERCEPT system is approved for use in the USA. While yet to receive regulatory approval, the THER-AFLEX UV-Platelets system (MacoPharma; referred to herein as UVC) is attractive as it does not require a photosensitising agent [12] . UVC-PI combines UVC light (target 254 nm) with strong agitation to inactivate pathogens [12, 13] . However, UVC-PI treatment also alters aspects of platelet quality, including acceleration of glycolytic metabolism, increased phosphatidylserine exposure and activation of the GPIIb/IIIa receptor [12, [14] [15] [16] .
Cold-storage of PI-treated platelets may enable an extension of the platelet shelf-life as both limiting factors (risk of bacterial growth and the storage lesion) would be mitigated. As such, the aim of this study was to characterise changes in platelet metabolism, phenotype and function occurring following UVC-treatment and subsequent cold-storage.
Materials and methods

Platelet preparation and UVC-treatment
This study had approval from the Australian Red Cross Blood Service Ethics Committee. All donations were from eligible, voluntary donors. Platelets concentrates were prepared in 30% plasma/70% SSP+ (MacoPharma, Mouvaux, France) from whole blood as previously described [17] .
On day 1 post-collection, two buffy coat-derived, ABOmatched platelet concentrates were pooled and split to create two homogenous platelet units. All units were transferred to an illumination kit, consisting of an illumination and storage bag (MacoPharma), via sterile connection. One unit was treated with the THERAFLEX UV-Platelets system as per the manufacturer's instructions (MacoPharma), while the other unit remained untreated. Subsequently both units were split and transferred into two half-bags to create a total of four discrete platelet units. The integrated storage bag was heat sealed in half to ensure the appropriate surface area/volume ratio for gas exchange as that in a standard volume platelet concentrate [18] . The units were then stored at room temperature (20-24°C) or in the cold (2-6°C), resulting in the following treatment groups: RT untreated, RT-UVC, cold untreated and cold-UVC (n = 8 for each group).
The RT platelets were stored at 20-24°C on a platelet agitator (Helmer Inc., Noblesville, IN, USA). The cold platelets were stored in a refrigerator at 2-6°C without agitation. Prior to sampling, the cold units were transferred to RT storage with agitation for approximately 10 min [8] . Platelet swirl and presence of aggregates were determined to be present or absent by macroscopic inspection of the bags prior to sampling. Platelet samples (15 ml) were taken on day 1 (from the initial pool prior to UVC-treatment), 2, 5, 7 and 9 by sterile-docking of a sample pouch.
In vitro In vitro quality analysis
The platelet count and mean platelet volume (MPV) were determined using a haematology analyser (CellDyn Emerald; Abbott Laboratories, Abbott Park, IL, USA). The pH was measured with a pH meter at 22°C (SevenExcellent pH Meter; Mettler Toledo, Columbus, OH, USA). Supernatants were prepared by centrifugation at 16009 g for 20 min, followed by 12 0009 g for 5 min at RT. The supernatants were stored at -80°C until batch testing was performed.
Total protein was measured from platelet supernatant, using a bicinchoninic acid (BCA) protein assay, as per the manufacturer's instructions (Pierce Biotechnology, Rockford, IL, USA), and was used to calculate plasma carryover [7] . The concentration of glucose in the supernatant was measured using a colorimetric assay (Thermo Fisher Scientific, Waltham, MA, USA) against a standard curve (Cayman Chemical, Ann Arbor, MI, USA). Supernatant lactate was measured using a commercially available kit for L-Lactate against a standard curve, according to the manufacturer's instructions (Abcam, Cambridge, United Kingdom). The rate of glucose consumption and lactate production was calculated by dividing the change in metabolite concentration by the cell count on each day.
Hypotonic shock response (HSR) was measured with a platelet aggregometer (Helena Laboratories, Beaumont, TX, USA) using previously established methods [17] . Platelet aggregation was measured using light transmission aggregometry (LTA; Helena Laboratories) in the absence of agonist stimulation, or in response to 20 lM adenosine diphosphate (ADP; Sigma, MO, USA) and 10 lg/ml collagen (Helena Laboratories), over a five minute period [17] .
For thromboelastography (TEG 5000, Haemoscope Corporation, Niles, IL, USA), platelets were diluted to 200 9 10 9 /l in freshly thawed plasma. The samples were activated using kaolin and calcium chloride (Haemonetics Corporation, Braintree, MA, USA) prior to application to a plain cup, as previously described [19] . The surface expression of platelet proteins was measured by flow cytometry (FACSCanto II; Becton Dickinson, Franklin Lakes, NJ, USA). Platelets (3 9 10 6 in Tyrode's buffer) were stained with the following antibodies: anti-CD41a-PE, anti-CD42b-PE (HIP1), anti-CD62P-PE, PAC-1-FITC (all from BD Biosciences, San Diego, CA, USA), anti-CD42b-PE (AN51; Dako, Glostrup, Denmark), anti-GPVI-eFluor nanocrystal 660 (eFluor660; eBioscience Inc., San Diego, CA, USA). Of the two antibody clones used to interrogate GPIba, HIP1 recognises the resting conformation and AN51 recognises an altered conformation of GPIba, where a reduction in binding of AN51 is associated with cold-induced clustering [20] . Phosphatidylserine externalisation was measured using annexin V binding, where platelets (1 9 10 6 in calcium containing buffer) were stained with annexin V-FITC (BioLegend, San Diego, CA, USA) and incubated for 15 min in the dark. Mitochondrial membrane potential was measured by uptake of tetramethylrhodamine ethyl ester (TMRE), where high TMRE fluorescence suggests active mitochondria and the converse indicates mitochondrial damage. Platelets (1 9 10 6 cells in Tyrode's buffer) were stained with 100 nM TMRE (Abcam, Cambridge, UK) and incubated for 20 min in the dark. The median fluorescence intensity (MFI) and percentage of positive cells were determined by flow cytometry after collecting 10 000 events. The absolute number of microparticles in the platelet concentrates was determined using TruCount tubes (BD Biosciences) and flow cytometry as previously described [19] . Platelet microparticles were defined as events ≤1Á0 lm that stained positively for CD61-APC (Dako) and annexin-V-FITC.
The concentration of soluble CD62P, RANTES (R&D Systems Inc., Minneapolis, MN, USA) and GPV (Diagnostica Stago Ltd, Asnieres, France) was measured from the platelet supernatant using commercially available ELISA kits, according to the manufacturer's instructions.
Statistical analysis
Data were analysed using GRAPHPAD PRISM 7Á03 (GraphPad Software Inc.; La Jolla, CA, USA) and are expressed as mean -standard deviation (SD). Comparisons were performed using a repeated measures two-way analysis of variance (ANOVA), with post-hoc Bonferroni's multiple comparisons test performed to determine the difference between the treatment groups over the entire storage period, rather than differences between each group on individual days. Linear regression with Pearson's correlation (r value) was performed to assess relationships between parameters. A P-value of less than 0Á05 was considered to be significant.
Results
Prior to treatment, the platelet components had the following specifications: volume 361 -4 ml; concentration 876 -60 9 10 9 /l and plasma carryover: 30 -3%. The unit volumes (RT: 174 -3 ml; RT-UVC: 174 -3 ml; Cold: 174 -2 ml; Cold-UVC: 175 -2 ml; P = 0Á279) and platelet concentration did not statistically differ between the four study groups (Fig. 1a) . Platelet swirling was observed in both RT groups until day 9, while swirl was absent from day 2 in the units stored in the cold. Macroscopic aggregates were not observed in any unit during storage. The MPV was stable during storage at RT, while cold-storage and UVC-treatment caused an initial increase in MPV (Fig. 1b) . However, the cold-UVC platelets displayed an increase in MPV which was greater than the additive effect of the individual treatments. The glucose concentration decreased over storage in all four study groups, and was below the limit of detection in the RT-UVC platelets by day 9 (data not shown). The average rate of glucose consumption over storage at RT was exacerbated by UVC-treatment, whilst cold storage of UVC-treated platelets inhibited the accelerated glucose consumption (Fig. 1c) . Consistent with this, the lactate concentration increased over storage, with the RT-UVC group showing the greatest accumulation of lactate (data not shown). The lactate production rate was increased by UVC treatment, whilst the cold-UVC platelets produced less lactate than the RT-UVC control (Fig. 2d) . The metabolic rates were compared between day 1 and day 7 only, due to the impact of glucose exhaustion in the RT-UVC group at later time points negatively affecting these rates. Despite these differences in glycolysis, the pH was not statistically different between the groups, which is likely due to the buffering capacity of the additive solution [21] . The pH of the platelets increased from 7Á04 -0Á04 on day 1 to 7Á14 -0Á06 on day 9 in the RT platelets, whilst the RT-UVC platelets showed a trend towards a lower pH (7Á08 -0Á07). The pH of both cold-stored groups remained low throughout storage (cold: 7Á02 -0Á08; cold-UVC: 7Á01 -0Á05 on day 9). The mitochondrial membrane potential, as evidenced by TMRE staining, was marginally reduced by cold-storage and further exacerbated in the cold-UVC group (Fig. 1e) . Interestingly, significant hyperpolarisation of the mitochondrial membrane potential was evident in the RT-stored units, which has recently been reported to occur in stored platelets [22] . The precise mechanism mediating this change is not well established. The HSR of RT platelets decreased over storage, which was exacerbated by UVC treatment and cold storage. The cold-UVC Fig. 1 Cold storage and UVC-treatment differentially affect platelet metabolic parameters. Platelets were either untreated or pathogen inactivated (UVC) and stored at room temperature (RT or RT-UVC) or in the cold (cold or cold-UVC). The (a) platelet count and (b) mean platelet volume were analysed using a haematology analyser. The average daily rate of (c) glucose consumption and (d) lactate production between day 1 and day 7 was calculated. (e) The mitochondrial membrane potential was determined by tetramethylrhodamine ethyl ester (TMRE) staining and flow cytometry. (f) The hypotonic shock response (HSR) was calculated based on a change in light transmission in response to the addition of phosphate buffered saline and water. The data represents the mean -SD (error bars) from n = 8 platelet concentrates. *P < 0Á05 between the indicated groups over storage. [Colour figure can be viewed at wileyonlinelibrary.com] group demonstrated a greater decrease in HSR than either of the individual treatments, with almost complete loss of recovery from day 2 of storage ( Fig. 1f) . Over storage, the decline in HSR was associated with mitochondrial depolarisation (r = -0Á5829; P < 0Á0001), and the MPV (r = 0Á8233; P < 0Á0001), where the cold-UVC platelets were the largest cells with the greatest mitochondrial membrane depolarisation and unable to recover from osmotic stress.
The proportion of platelets expressing GPIIb (CD41) remained stable and similar in all platelet groups, regardless of treatment or storage temperature (Fig. 2a) . However, individually, UVC-treatment and cold-storage both increased the abundance of activated GPIIb/IIIa (PAC-1 binding; Fig. 2b ). This increase was further exacerbated in the cold-UVC group. While cold-storage and UVCtreatment individually reduced the proportion of platelets expressing the resting conformation of GPIba (CD42b: HIP1), the cold-UVC platelets had similar receptor abundance to cold platelets (Fig. 2c) . Similar results were seen with clustered GPIba (CD42b:AN51), indicating no additive effect due to the combination of cold-storage and UVC-treatment (Fig. 2d) . GPVI abundance decreased over storage for all four treatment groups. While the cold-UVC platelets had the lowest abundance of this receptor, the difference was not statistically significant compared to cold or UVC-treated groups (Fig. 2e) . Alterations to surface GPV were indirectly assessed by measurement of soluble GPV in the supernatant (Fig. 2f) . Although there was an increase in soluble GPV over storage, and a trend for greater release in the UVC-treated groups, there were no statistical differences. P-selectin surface expression (CD62P) increased slightly during RT storage, with a non-significant increase observed following UVC-treatment (Fig. 3a) . The cold and cold-UVC platelets had significantly increased P-selectin expression; however this appears to be primarily mediated by cold-storage. There were no significant differences in the release of soluble CD62P into the supernatant (Fig. 3b) . Minimal phosphatidylserine externalisation (annexin-V) was observed in the untreated platelets regardless of storage temperature (Fig. 3c) . However, UVC-treatment of platelets resulted in an increase in annexin-V binding, which was exacerbated when combined with cold-storage. The microparticle concentration increased over storage in all groups (Fig. 3d) , with incremental increases induced by cold-storage and UVC-treatment. However, the combination of UVC-treatment and cold storage synergistically exacerbated microparticle formation. Alpha-granule contents were released into the supernatant of platelet components during storage, as exemplified by RANTES. As expected, cold-storage inhibited cytokine release compared to RT, while UVC-treatment had little effect (Fig. 3e) .
Aggregation in response to both ADP and collagen decreased over storage in the RT-stored groups (Fig. 4a,b) . While cold-storage potentiated agonist-induced aggregation, UVC-treatment had little impact. Interestingly, in the absence of an agonist, cold-stored platelets displayed almost no spontaneous aggregation (<1%), compared to approximately 3-5% basal aggregation in RT-stored platelets and approximately 10-15% in cold-UVC platelets (P < 0Á001). Spontaneous aggregation was not impacted by storage duration, but was associated with PAC-1 binding (Fig. 4c) . TEG was used to assess global clotting potential. Cold storage resulted in a minor reduction in the reaction time (R time; time to clot formation), which was further reduced by combined cold-UVC treatment, although these differences were not statistically significant (Fig. 4d) . Further, there were no differences in the strength of clot (MA), K-time and alpha angle between any of the groups (data not shown).
Discussion
Currently there is international interest in both cold-storage and different PI systems as strategies to alleviate issues related to RT storage of platelets [4, 23] . UVCtreatment is known to affect standard in vitro quality parameters, however, most changes are small and do not become evident until later in storage [14, 16, 24, 25] . It was hypothesised that cold-storage of UVC-treated platelets may reduce some of the effects associated with RT storage of PI-treated platelets in the hope of extending the shelf-life. However, when directly compared, cold-storage alone led to more extensive changes to platelet parameters than UVC treatment. Interestingly, when UVCtreated platelets were cold-stored, the platelet quality parameters were differentially affected.
As anticipated, cold-storage was sufficient to prevent the accelerated glycolytic metabolism associated with UVC-treatment. The availability of an adequate supply of energy during ex vivo storage has a substantial impact on platelets, with depletion of glucose being linked with decreased viability [26] . Thus, the reduction in glycolytic metabolism afforded by cold storage provided UVC-treated platelets with sufficient glucose for at least an extra two days of storage, compared to RT-UVC platelets which had exhausted their glucose reserves by day 7. However, the combination of UVC-treatment and cold-storage also induced mitochondrial damage. The disruption to mitochondrial integrity may also contribute to membrane instability and cell swelling [27] .
Cold-storage is known to induce a rapid morphological change in platelets, from a discoid to a spheroid morphology, resulting in increased MPV, loss of platelet swirl and reduced HSR [6, 28, 29] . UVC-treatment has similar effects on the MPV and HSR [16, 24, 25] . In the individual treatment arms, the MPV remained constant after the initial insult (UVC treatment or cold storage) on day 2, whereas the MPV continued to increase in the cold-UVC platelets, suggesting it may be due to more than just a morphological change. Cell morphology, as well as the combined response of a complex series of ionic channels, membrane receptors and intracellular activities regulates the recovery from hypotonic shock [30, 31] , which is reflected in this study by the associations between the MPV, HSR and TMRE staining. It remains to be seen whether the loss of HSR in the cold-UVC platelets may negatively impact platelet survival following transfusion [30, 32] . However, given that the likely recipients of cold Fig. 2 Cold storage and UVC-treatment differentially affect surface abundance and conformation of platelet glycoproteins. Platelets were either untreated or pathogen inactivated (UVC) and stored at room temperature (RT or RT-UVC) or in the cold (cold or cold-UVC). Flow cytometry was used to measure the mean fluorescence intensity (MFI) of (a) GPIIb using anti-CD41a, (b) activated GPIIb/IIIa using PAC-1, (c) GPIba using anti-CD42b (HIP1), (d) clustered GPIba using anti-CD42b (AN51) and (e) GPVI using anti-GPVI. (f) Soluble GPV was measured from the supernatant using a commercially available ELISA kit. The data represents the mean -SD (error bars) from n = 8 platelet concentrates. *P < 0Á05 between the indicated groups over storage. [Colour figure can be viewed at wileyonlinelibrary.com] platelets will be those who are actively bleeding [4] , the length of in vivo survival may not be the most relevant indicator of quality.
Changes in the abundance or conformation of platelet surface receptors can provide valuable information regarding platelet quality. Although UVC-treatment alone induced GPIba clustering, when combined with cold-storage, there was no additional clustering above what could be expected with cold-storage [33] . While it is known that both cold-storage and UVC-PI independently activate the GPIIb/IIIa receptor (increased PAC-1 binding) [34, 35] , it was intriguing to find that cold-storage of UVC-treated platelets potentiated this response above the combined effect of the individual treatments. Further work is required to understand the mechanisms mediating this synergistic effect, as the UVC-PI effect is mediated by Fig. 3 Cold storage and UVC-treatment differentially modulate platelet activation markers. Platelets were either untreated or pathogen inactivated (UVC) and stored at room temperature (RT or RT-UVC) or in the cold (cold or cold-UVC). (a) Flow cytometry was used to measure the proportion of platelets staining positively for P-selectin using anti-CD62P. (b) Soluble CD62P was measured from the supernatant using a commercially available ELISA kit. (c) Flow cytometry was used to measure the proportion of platelets staining positively for phosphatidylserine using annexin-V (d) Platelet supernatant was incubated with anti-CD61-PE and annexin-V-FITC in TruCount tubes and microparticles were enumerated by flow cytometry. (e) RANTES was measured from the supernatant using a commercially available ELISA kit. The data represents the mean -SD (error bars) from n = 8 platelet concentrates. *P < 0Á05 between the indicated groups over storage. [Colour figure can be viewed at wileyonlinelibrary.com] modification of the disulphide bonds regulating the conformational structure of GPIIb/IIIa [35] , while the coldinduced activation is reportedly calcium-dependent [9] . Similarly, the combination of cold-storage and UVCtreatment resulted in a synergistic increase in externalised phosphatidylserine and the release of phosphatidylserineexpressing microparticles. Phosphatidylserine externalisation and microparticle formation are often associated with apoptosis, especially when combined with mitochondrial dysfunction [36] . While there was only a weak relationship between the TMRE and annexin-V staining when all groups were analysed (r = -0Á3821; P < 0Á001), there was a much stronger association between these parameters in the cold-UVC group alone (r = -0Á6307; P < 0Á001), suggesting that mitochondrial membrane depolarisation contributes to phosphatidylserine externalisation in this group. Alternatively, it would be of interest to determine whether the distinctive membrane changes observed in the cold-UVC group were due to alterations in the lipid microenvironment and downstream signal transduction [37] .
Cold-stored platelets release fewer soluble proteins into the surrounding milieu than platelets stored at room temperature, presumably due to better retention of their alpha-granules [7, 8, 10] . However, cold-stored platelets also demonstrate greater surface expression of P-selectin [3, 34] , which is also released from alpha-granules. While further work is required to understand these counterintuitive results, it has been proposed that soluble and membrane-bound proteins are compartmentalised within different alpha-granule sub-types and their release may be governed by distinct mechanisms [38] . Further, UVC-PI has little effect on the release of the alpha-granule proteins assessed.
The improved haemostatic function afforded by cold-storage [2, 6, 8] was not negatively impacted by UVC-treatment. The cold-UVC platelets demonstrated high spontaneous aggregation by LTA, which is likely Fig. 4 Cold storage and UVC-treatment differentially affect platelet functional parameters. Platelets were either untreated or pathogen inactivated (UVC) and stored at room temperature (RT or RT-UVC) or in the cold (cold or cold-UVC). Light transmission aggregometry was used to measure maximum aggregation in response to (a) 20 lM ADP, (b) 100 lg/ml collagen. (c) Individual data points for aggregation in the absence of agonist stimulation was plotted against PAC-1 binding on day 2. (d) Clot formation was measured using thromboelastography; time to clot initiation (reaction time) is presented. The data represents the mean -SD (error bars) from n = 8 platelet concentrates. *P < 0Á05 between the indicated groups over storage. [Colour figure can be viewed at wileyonlinelibrary.com] mediated by PI-treatment, as this has also been observed during RT-storage of Mirasol-PI platelets [39] , whereas the untreated cold-stored group demonstrated significantly less basal aggregation than the other groups. However, the enhanced basal aggregation did not seem to influence the agonist-induced aggregation responses or other functional outputs.
One limitation of this study was the use of half-sized units to assess the impact of cold-storage and UVCtreatment. Whilst an effort was made to maintain the correct surface area to volume ratio by splitting each unit in two into half-sized platelet bags [18] , it is nonetheless a change that could reduce the generalisability to standard platelet storage. However, the results from the RT, cold and RT UVC-PI platelet groups are inline with previously published data generated using standard platelet storage bags [6, 10, 16, 25] , thus indicating that the use of the half-sized bags did not impact the validity of the results.
This study focused on UVC-PI technology, as it is does not require a photosensitising agent and is thought to induce less platelet damage than other PI systems [23] . However, as each PI system has different effects on platelet parameters, it will also be important to understand the effect of cold-storage of platelets following treatment with the other two PI systems.
In summary, this study has demonstrated that treatment of platelets with the UVC-PI system followed by cold-storage results in a phenotype that is more closely aligned with standard cold-stored platelets rather than UVC-treated platelets. While cold-storage provided the benefit of inhibiting accelerated glycolysis that is characteristic of UVC-treated platelets, it also exaggerated certain effects of each individual treatment, particularly those associated with the platelet membrane. This study presents novel data to support the possibility of producing a platelet component that may be safer and more haemostatically functional than conventional RT-stored platelets, with a longer shelf-life. Further characterisation is warranted to assess the feasibility of cold-UVC platelets as a transfusable product. 
